Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Diagnosis of intrahepatic cholangiocarcinoma
Child-Pugh class A liver function
Planned neoadjuvant treatment with gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor
Planned anatomical hemihepatectomy with an expected future liver remnant greater than 40%
Age 18 to 75 years
Willing and able to participate and provide written informed consent
No acute illness or significant worsening of symptoms within 4 weeks before enrollment

Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury